share print

Board of directors

Our directors embody our dream, dare, share culture, providing strategic oversight to boost innovation, develop treatments in unmet areas of healthcare and support progress to address the challenges of the future.
Each member of the board brings to the table their own unique skill-set and is instrumental in driving us forward with continued success. 

Erin Gainer

Erin Gainer

Chair of the Board

Dr. Gainer is Chair of the Board of HRA Pharma. Before that she was CEO of the company for 7 years. Over her tenure, company’s revenues more than tripled and profits increased 10-fold. Dr. Gainer joined HRA Pharma in 2000 in order to lead the development of the new chemical entity, ulipristal acetate. As Executive Director of Research and Development, she spent nearly a decade managing HRA Pharma's global R&D program focused on designing innovative products that respond to unmet medical needs in the fields of reproductive health and rare endocrine disease. She is the author/inventor of dozens of peer-reviewed publications and patents.

Key knowledge:

Erin Gainer

Erin Gainer

IRELAND USA

Chair of the Board

Dr. Gainer is Chair of the Board of HRA Pharma. Before that she was CEO of the company for 7 years. Over her tenure, company’s revenues more than tripled and profits increased 10-fold. Dr. Gainer joined HRA Pharma in 2000 in order to lead the development of the new chemical entity, ulipristal acetate. As Executive Director of Research and Development, she spent nearly a decade managing HRA Pharma's global R&D program focused on designing innovative products that respond to unmet medical needs in the fields of reproductive health and rare endocrine disease. She is the author/inventor of dozens of peer-reviewed publications and patents.

Clover Bergmann

Clover Bergmann

Director (Independent)

 Ms. Bergmann is a highly experienced consumer products executive with more than 30 years of success in leadership roles with leading consumer companies, including Sara Lee, Schering-Plough and Johnson & Johnson.  She managed the global women’s health business at Johnson & Johnson and remains involved in women’s issues through her service to two non-profit boards, EngenderHealth and Women in Need. She is currently an Adjunct Professor in Marketing and General Management at New York University (NYU). 

Key knowledge:

Clover Bergmann

Clover Bergmann

USA

Director (Independent)

Ms. Bergmann is a highly experienced consumer products executive with more than 30 years of success in leadership roles with leading consumer companies, including Sara Lee, Schering-Plough and Johnson & Johnson. She managed the global women’s health business at Johnson & Johnson and remains involved in women’s issues through her service to two non-profit boards, EngenderHealth and Women in Need. She is currently an Adjunct Professor in Marketing and General Management at New York University (NYU).

Michael Bruun

Michael Bruun

Director (Goldman Sachs Merchant Banking Division)

Mr. Bruun is a managing director in the Merchant Banking Division (MBD) of Goldman Sachs in London. He is responsible for corporate European healthcare and nutrition investing and corporate investing in Scandinavia. Previously, he was an associate in the Nordic Mergers & Acquisitions team in the Investment Banking Division (IBD). He joined Goldman Sachs in 2004, became managing director in 2013 and was named partner in 2016.

Key knowledge:

Michael Bruun

Michael Bruun

Director (Goldman Sachs Merchant Banking Division)

Mr. Bruun is a managing director in the Merchant Banking Division (MBD) of Goldman Sachs in London. He is responsible for corporate European healthcare and nutrition investing and corporate investing in Scandinavia. Previously, he was an associate in the Nordic Mergers & Acquisitions team in the Investment Banking Division (IBD). He joined Goldman Sachs in 2004, became managing director in 2013 and was named partner in 2016.

Judith Charpentier

Judith Charpentier

Director (Astorg Partners)

Ms. Charpentier is a Director in the Investment team of Astorg Partners. Prior to joining Astorg Partners, Ms. Charpentier was an Associate at Fondations Capital Services France SASU, a private equity fund in Paris. She started her career in 2005, as a Principal in the M&A Division of Morgan Stanley in Paris, before joining the Media and Telecommunication division in New York.

Key knowledge:

Judith Charpentier

Judith Charpentier

FRANCE

Director (Astorg Partners)

Ms. Charpentier is a Director in the Investment team of Astorg Partners. Prior to joining Astorg Partners, Ms. Charpentier was an Associate at Fondations Capital Services France SASU, a private equity fund in Paris. She started her career in 2005, as a Principal in the M&A Division of Morgan Stanley in Paris, before joining the Media and Telecommunication division in New York.

David Colpman

David Colpman

Director (Independent)

 Mr. Colpman brings over 30 years of broad experience in business development to HRA Pharma. He is the founder of Colpman Consulting Ltd, a company providing strategic advice to a variety of biotech and pharma companies. Previously he headed business development and licensing at Shire PLC  and has also held various BD roles at Purdue, Novo Nordisk A/S, Boots Pharmaceuticals and Glaxo. Mr. Colpman is on the Board of Orexo AB a specialty pharmaceutical company commercialising a product for opioid dependence.  

Key knowledge:

David Colpman

David Colpman

Director (Independent)

Mr. Colpman brings over 30 years of broad experience in business development to HRA Pharma. He is the founder of Colpman Consulting Ltd, a company providing strategic advice to a variety of biotech and pharma companies. Previously he headed business development and licensing at Shire PLC and has also held various BD roles at Purdue, Novo Nordisk A/S, Boots Pharmaceuticals and Glaxo. Mr. Colpman is on the Board of Orexo AB a specialty pharmaceutical company commercialising a product for opioid dependence.

Tim Corn

Tim Corn

Director (Independent)

Dr. Corn brings in-depth scientific, medical and regulatory knowledge to HRA Pharma. He was previously Chief Medical Officer at Jazz Pharmaceuticals International plc (formerly EUSA Pharma) and Zeneus Pharma. He has held senior clinical and regulatory positions at GlaxoWellcome, MSD Research Laboratories, Athena Neuroscience and Elan as well as in the UK regulatory agency. Dr. Corn has played a key role in more than twenty regulatory approvals in USA and Europe and has solid experience both as a board member and chair of a number of healthcare companies and charities.

Key knowledge:

Tim Corn

Tim Corn

Director (Independent)

Dr. Corn brings in-depth scientific, medical and regulatory knowledge to HRA Pharma. He was previously Chief Medical Officer at Jazz Pharmaceuticals International plc (formerly EUSA Pharma) and Zeneus Pharma. He has held senior clinical and regulatory positions at GlaxoWellcome, MSD Research Laboratories, Athena Neuroscience and Elan as well as in the UK regulatory agency. Dr. Corn has played a key role in more than twenty regulatory approvals in USA and Europe and has solid experience both as a board member and chair of a number of healthcare companies and charities.

Karsten Langer

Karsten Langer

Observer (The Riverside Company)

Mr. Langer is a Brussels-based partner at the Riverside Company, a minority investor in HRA Pharma since 2011. He heads Riverside's investment activities in parts of continental Europe. Prior to joining Riverside, Mr. Langer was Managing Partner of an independent corporate finance firm, advising on acquisitions and divestitures across Europe. Before that, he spent five years at GE Capital in Europe, in operating management and investment roles. He started his career with Danske Bank in Copenhagen.

 

Key knowledge:

Karsten Langer

Karsten Langer

NORWAY

Observer (The Riverside Company)

Mr. Langer is a Brussels-based partner at the Riverside Company, a minority investor in HRA Pharma since 2011. He heads Riverside's investment activities in parts of continental Europe. Prior to joining Riverside, Mr. Langer was Managing Partner of an independent corporate finance firm, advising on acquisitions and divestitures across Europe. Before that, he spent five years at GE Capital in Europe, in operating management and investment roles. He started his career with Danske Bank in Copenhagen.

Olivier Lieven

Olivier Lieven

Director (Astorg Partners)

 Mr. Lieven is an Analyst and member of the Investment team of Astorg Partners. Prior to this, he worked for three years in the infrastructure investment division of 3i. Mr. Lieven started his career at Barclays Infrastructure Funds in 2012.

Key knowledge:

Olivier Lieven

Olivier Lieven

FRANCE

Director (Astorg Partners)

Mr. Lieven is an Analyst and member of the Investment team of Astorg Partners. Prior to this, he worked for three years in the infrastructure investment division of 3i. Mr. Lieven started his career at Barclays Infrastructure Funds in 2012.

Scarlett Omar-Broca

Scarlett Omar-Broca

Director (Goldman Sachs Merchant Banking Division)

Ms. Omar Broca is Executive Director with Goldman Sachs in London since 2007. Her area of expertise is private equity. Previously, Scarlett Omar-Broca worked as an Analyst with Merrill Lynch.

 

Key knowledge:

Scarlett Omar-Broca

Scarlett Omar-Broca

Director (Goldman Sachs Merchant Banking Division)

Ms. Omar Broca is Executive Director with Goldman Sachs in London since 2007. Her area of expertise is private equity. Previously, Scarlett Omar-Broca worked as an Analyst with Merrill Lynch.

Thierry Timsit

Thierry Timsit

Director (Astorg Partners)

 Mr. Timsit is the Co-Founder and a Managing Partner and Owner of Astorg Partners. He is a member of the Investment team. Additionally, he is in charge of the company’s Investor Relations team. Prior to this, he spent 4 years with the private equity team at Suez. He began his carrier in 1989 at Banque Indosuez where he held several positions in London and Paris, particularly in the project finance division. 

Key knowledge:

Thierry Timsit

Thierry Timsit

FRANCE

Director (Astorg Partners)

Mr. Timsit is the Co-Founder and a Managing Partner and Owner of Astorg Partners. He is a member of the Investment team. Additionally, he is in charge of the company’s Investor Relations team. Prior to this, he spent 4 years with the private equity team at Suez. He began his carrier in 1989 at Banque Indosuez where he held several positions in London and Paris, particularly in the project finance division.

André Ulmann

André Ulmann

Director

Dr. Ulmann is the Founder of HRA Pharma, a company he led from 1996 to 2009 as CEO, then he chaired until 2016. Currently he is the CEO of CEMAG Consulting and serves as a consultant for several start-up companies. Before founding HRA Pharma, Dr. Ulmann served as Medical Director and Head of Clinical Research for Roussel-Uclaf and Hoechst-Marion-Roussel. Prior to that, he was international project leader for the development of RU-486, then medical director of Laboratoire Roussel, France. He began his career as a physician at the Necker Hospital of Paris.

Key knowledge:

André Ulmann

André Ulmann

FRANCE

Director

Dr. Ulmann is the Founder of HRA Pharma, a company he led from 1996 to 2009 as CEO, then he chaired until 2016. Currently he is the CEO of CEMAG Consulting and serves as a consultant for several start-up companies. Before founding HRA Pharma, Dr. Ulmann served as Medical Director and Head of Clinical Research for Roussel-Uclaf and Hoechst-Marion-Roussel. Prior to that, he was international project leader for the development of RU-486, then medical director of Laboratoire Roussel, France. He began his career as a physician at the Necker Hospital of Paris.

closeyou are leaving hra pharma
You are now leaving www.hra-pharma.com and being redirected to an external website which might not be under control of HRA Pharma.
do you want to proceed ?